BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guerra B, Recio C, Aranda-Tavío H, Guerra-Rodríguez M, García-Castellano JM, Fernández-Pérez L. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Front Oncol 2021;11:626971. [PMID: 33718197 DOI: 10.3389/fonc.2021.626971] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Wen G, Xu X, Xia P. Metabolism in Cancer Stem Cells: Targets for Clinical Treatment. Cells 2022;11:3790. [DOI: 10.3390/cells11233790] [Reference Citation Analysis]
2 Sifaoui I, Díaz-Rodríguez P, Rodríguez-Expósito RL, Reyes-Batlle M, Lopez-Arencibia A, Salazar Villatoro L, Castelan-Ramírez I, Omaña-Molina M, Oliva A, Piñero JE, Lorenzo-Morales J. Pitavastatin loaded nanoparticles: a suitable ophthalmic treatment for Acanthamoeba Keratitis inducing cell death and autophagy in Acanthamoeba polyphaga. Eur J Pharm Biopharm 2022:S0939-6411(22)00215-6. [PMID: 36162636 DOI: 10.1016/j.ejpb.2022.09.020] [Reference Citation Analysis]
3 Aldaalis A, Bengoechea-alonso MT, Ericsson J. The SREBP-dependent regulation of cyclin D1 coordinates cell proliferation and lipid synthesis. Front Oncol 2022;12:942386. [DOI: 10.3389/fonc.2022.942386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pereira M, Matuszewska K, Glogova A, Petrik J. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy. Cancers 2022;14:3500. [DOI: 10.3390/cancers14143500] [Reference Citation Analysis]
5 McCubrey JA, Yang LV, Abrams SL, Steelman LS, Follo MY, Cocco L, Ratti S, Martelli AM, Augello G, Cervello M. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells 2022;11:2155. [PMID: 35883598 DOI: 10.3390/cells11142155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Centonze G, Natalini D, Piccolantonio A, Salemme V, Morellato A, Arina P, Riganti C, Defilippi P. Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. Front Oncol 2022;12:906670. [PMID: 35719918 DOI: 10.3389/fonc.2022.906670] [Reference Citation Analysis]
7 Lee D, Rosenthal CJ, Penn NE, Dunn ZS, Zhou Y, Yang L. Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy. Cancers (Basel) 2022;14:3005. [PMID: 35740670 DOI: 10.3390/cancers14123005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Currivan E, Finlay D, Moreira D. Dendritic cells metabolism: a strategic path to improve antitumoral DC vaccination. Clin Exp Immunol 2022;208:193-201. [PMID: 35537194 DOI: 10.1093/cei/uxac048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chiarella E, Nisticò C, Di Vito A, Morrone HL, Mesuraca M. Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs. Biomedicines 2022;10:1146. [DOI: 10.3390/biomedicines10051146] [Reference Citation Analysis]
10 Menendez JA, Lupu R. Fatty acid synthase: A druggable driver of breast cancer brain metastasis. Expert Opin Ther Targets 2022. [PMID: 35545806 DOI: 10.1080/14728222.2022.2077189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Göbel A, Riffel RM, Hofbauer LC, Rachner TD. The mevalonate pathway in breast cancer biology. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xiao Y, Liu Q, Peng N, Li Y, Qiu D, Yang T, Kang R, Usmani A, Amadasu E, Borlongan CV, Yu G. Lovastatin Inhibits RhoA to Suppress Canonical Wnt/β-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer. Cell Transplant 2022;31:9636897221075749. [PMID: 35168393 DOI: 10.1177/09636897221075749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, Tsutsumi K. Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals 2022;15:151. [DOI: 10.3390/ph15020151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Pikuleva IA. Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases. Explor Neuroprotective Ther 2021;1:159-72. [PMID: 35156102 DOI: 10.37349/ent.2021.00013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Alderweireldt E, Grootaert C, De Wever O, Van Camp J. A two-front nutritional environment fuels colorectal cancer: perspectives for dietary intervention. Trends Endocrinol Metab 2021:S1043-2760(21)00261-7. [PMID: 34887164 DOI: 10.1016/j.tem.2021.11.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Bertok T, Pinkova Gajdosova V, Bertokova A, Svecova N, Kasak P, Tkac J. Breast cancer glycan biomarkers: their link to tumour cell metabolism and their perspectives in clinical practice. Expert Rev Proteomics 2021;:1-30. [PMID: 34711108 DOI: 10.1080/14789450.2021.1996231] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ishikawa T, Osaki T, Sugiura A, Tashiro J, Warita T, Hosaka YZ, Warita K. Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells. Vet Comp Oncol 2021. [PMID: 34657361 DOI: 10.1111/vco.12778] [Reference Citation Analysis]
18 Zhou C, Wang Z, Cao Y, Zhao L. Pan-cancer analysis reveals the oncogenic role of 3-hydroxy-3-methylglutaryl-CoA synthase 1. Cancer Rep (Hoboken) 2021;:e1562. [PMID: 34549901 DOI: 10.1002/cnr2.1562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Shwe TH, Pothacharoen P, Phitak T, Wudtiwai B, Kongtawelert P. Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:8755. [PMID: 34445462 DOI: 10.3390/ijms22168755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zou H, Yang N, Zhang X, Chen HW. RORγ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. Biochem Pharmacol 2021;:114725. [PMID: 34384758 DOI: 10.1016/j.bcp.2021.114725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: A review. Biomed Pharmacother 2021;141:111858. [PMID: 34323700 DOI: 10.1016/j.biopha.2021.111858] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
22 Oscilowska I, Huynh TYL, Baszanowska W, Prokop I, Surazynski A, Galli M, Zabielski P, Palka J. Proline oxidase silencing inhibits p53-dependent apoptosis in MCF-7 breast cancer cells. Amino Acids 2021. [PMID: 34085157 DOI: 10.1007/s00726-021-03013-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]